ClinicalTrials.gg
CompletedNCT01839929PeACEUpdated May 1, 2013

A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF

A Phase 4 interventional study of Prograf and Advagraf in Kidney Transplantation, sponsored by Astellas Pharma Korea, Inc.. Completed at 4 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-05-01.

Sponsored by Astellas Pharma Korea, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
138
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy of tacrolimus modified release formulation Advagraf® after conversion from Prograf® in stable kidney transplant patients.

02

Conditions studied

  • Kidney Transplantation

Keywords

  • tacrolimus
  • immunosuppressant
  • FK506
03

In context

Lead sponsor

Astellas Pharma Korea, Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients received a kidney transplant at least 12 months ago prior to enrollment.
  2. Patients have taken unchanged dosage of Prograf® and remained stable serum level of tacrolimus at least for 12 weeks prior to enrollment.
  3. Patients have kept in unchanged therapy (combination therapy) at least for 12 weeks prior to enrollment.
  4. Female patients of must have a negative urine or serum pregnancy test prior to enrollment, and agreed to the deliberate prevention of conception during the trial.
  5. Patients are considered clinically stable by observer's judgment.
  6. Patients must understand the purpose and risk of participating the trial and signed on the written consent.

Exclusion criteria

Exclusion Criteria:

  1. Patients have previously received an organ transplant other than a kidney.
  2. Patients have had acute transplant rejection within 12 weeks, or acute transplant rejection requiring antilymphocyte therapy within 24 weeks prior to enrollment.
  3. Patients newly diagnosed malignant tumors after organ transplant but the patients treated completely with basal or squamous cell carcinoma of the skin are excepted.
  4. Patients have a known to Prograf® or tacrolimus.
  5. Patients whose medical condition are able to interfere with the study objectives.
  6. Patients who are at the risk of drug abuse or mental disorders or communicate difficulties with the observer.
  7. Patients have been participated in another clinical trial, or treated with drugs of clinical trial within 28 days prior to enrollment.
  8. Patients have been taken prohibited combination agents within 28 days prior to enrollment.
  9. Patients are pregnant or lactating.
  10. Patient are -positive.
  11. Patients are not able to keep the scheduled visit.
  12. Patients whose (MDRD) is in the level of \<30 mL/min.
  13. Patients who are at the condition of 'Creeping creatinine (defined by 20% increase within 6 months prior to enrollment)
  14. Patients whose /AST and/or SGOT/ALT levels have been elevated greater than 2 times the upper value of the normal range.
  15. Patients have FSGS or MPGN Type II as underlying diseases.
  16. Patients are with cirrhosis
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    Prograf/Advagraf

    conversion from Prograf to Advagraf

    Drug: Prograf · Drug: Advagraf

Interventions

  • oral

    Also known as: FK506, tacrolimus

  • oral

    Also known as: FK506E, tacrolimus modified release formulation

06

What researchers measure

Primary outcomes

  1. Change in glomerular filtration rate (GFR) at Week 24 from baseline

    Time frame: Baseline and Week-24

Secondary outcomes

  1. Change in Blood Pressure (BP) at Week 24 from baseline

    Time frame: Baseline and Week-24

  2. Change in HbA1c at Week 24 from baseline

    Time frame: Baseline and Week-24

  3. Change in tacrolimus blood trough level at Week 24 from baseline

    Time frame: Baseline and Week-24

  4. Safety assessed by the incidence of adverse events, physical exam., vital signs and labo tests

    Time frame: For 24 weeks

  5. Overall frequency of acute rejection

    Time frame: For 24 weeks

07

Study locations

4 sites
  • Busan, Korea, Republic of
  • Daegu, Korea, Republic of
  • Daejeon, Korea, Republic of
  • Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2013
First posted
Apr 25, 2013
Start
Sep 2010
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Last update
May 1, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01839929
Responsible party
Sponsor
First posted
Apr 25, 2013
Start date
Sep 2010
Primary completion
Feb 2013
Completion
Feb 2013
Last update
May 1, 2013

Study contacts

Medical Director
study director · Astellas Pharma Korea, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion